Content

The DSIP Peptide: A 1970s Sleep Mystery

Creator: Julian Reyes, Health Writer
Published: 2026-08-12

The DSIP peptide was isolated from the blood of sleeping rabbits in 1970s Switzerland, yet no one has ever found its receptor — or the gene that would prove mammals make it.

Julian Reyes, Health Writer August 12, 2026 8 min read

A woman sitting on a bed in warm evening lamplight, winding down before sleep

The short version

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide, about 850 daltons, isolated in 1970s Switzerland from the blood of rabbits in an induced sleep state and characterized in 1977.
Fifty years on, no DSIP receptor has been identified, and no gene encoding DSIP has been found in any mammal — whether it is a true endogenous human peptide is an open question.
The sleep evidence is thin and conflicting: small 1980s human studies (the largest series: 18 adults with chronic insomnia) reported improvements, a 2006 review found clearer slow-wave-sleep activity from synthetic analogues than from DSIP itself, and no modern placebo-controlled trial exists.
Older literature reports endocrine effects — reduced ACTH, increased growth-hormone and luteinizing-hormone release, somatostatin inhibition — and describes DSIP as a "stress-limiting factor."
On July 23–24, 2026, an FDA advisory committee voted 6–7–1 against adding DSIP to the 503A compounding bulks list; the vote is advisory and rulemaking is pending. A licensed provider may still prescribe — that decision sits between you and your doctor.
DSIP is not FDA-approved. Through Promise it is available only by prescription, prepared by a licensed U.S. compounding pharmacy.

In the 1970s, a research group in Basel, Switzerland, drew blood from the cerebral veins of rabbits in an induced sleep state and isolated a small peptide from it — a bet that sleep itself might circulate in the bloodstream. They called it delta sleep-inducing peptide, or DSIP, and half a century later, "what is DSIP?" is still a question science can only half answer. The characterization paper appeared in 1977; the receptor that would explain how the peptide works has never been found, and neither has the gene that would prove mammals make it. That absence makes DSIP one of the strangest molecules in the peptide catalog — and the unknowns deserve as much attention as the findings.

What is the DSIP peptide, exactly?

DSIP is a nonapeptide — a chain of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a mass of roughly 850 daltons. It is classified as a neuropeptide: a peptide understood to act primarily within the central nervous system, in DSIP's case on the pathways that regulate sleeping and waking.

Peptides as a class are short chains of amino acids that regulate an enormous range of bodily functions, and class membership says little about what any one molecule does. Semaglutide, for instance, is also a peptide — one that acts on metabolic regulation and weight, with at most an indirect influence on sleep. DSIP sits in a different corner of the family: the neuropeptides under investigation for sleep, neurological, and recovery questions.

The molecule was isolated from the cerebral venous blood of rabbits and characterized by G. A. Schoenenberger and M. Monnier in a 1977 paper in the Proceedings of the National Academy of Sciences. It is amphiphilic — comfortable in both watery and fatty environments — and the older literature reports that it crosses the blood–brain barrier and acts both centrally and peripherally. Advances in peptide synthesis long ago made DSIP straightforward to produce; availability was never the bottleneck. Understanding is.

Why sleep researchers cared: deep sleep and insomnia

Sleep cycles through light sleep, deep slow-wave sleep, and REM, and each phase has restorative roles. Slow-wave sleep is where physical repair, immune activity, and memory consolidation concentrate — growth-hormone secretion peaks there. Insomnia, meaning persistent difficulty falling or staying asleep, fragments exactly that phase. A peptide named for delta waves was always going to draw attention.

It is also the anabolic stretch of the night — cellular regeneration and repair peak while the brain runs its slowest rhythms, supporting cognitive resilience — which is why shortened or fragmented deep sleep brings fatigue, mood instability, and impaired physical restoration.

The problem is common. Roughly 10% of adults meet criteria for an insomnia disorder, and another 20% experience occasional insomnia symptoms, by a 2022 epidemiology review. Chronic insomnia is also bidirectionally associated with anxiety, depression, cardiovascular disease, and weakened immune function — the arrow runs both ways, and association is not the same as cause.

The missing receptor — and the missing gene

No receptor for DSIP has ever been identified — not in the 1970s, not since. No gene encoding DSIP has been found in rabbits, humans, or any other mammal. A 2006 review in the Journal of Neurochemistry called the peptide "a still unresolved riddle," and the description has not aged out.

This is not a technicality. A receptor is how a peptide acts on a cell; without one, there is no confirmed mechanism connecting DSIP to sleep or anything else. The review notes that DSIP's structure resembles no other known peptide family, and sequence-database searches align it most closely with a hypothetical protein from Amycolatopsis coloradensis — a soil bacterium. That raises a question fifty years of research has not closed: whether DSIP is an endogenous mammalian peptide at all.

There are threads. DSIP-like immunoreactivity — molecules that antibodies raised against DSIP will bind — shows up in neurosecretory nuclei of the hypothalamus across vertebrate species. But those regions are not particularly relevant to sleep regulation, and the review's authors propose the signal may belong to a related, still-unidentified peptide rather than DSIP itself. Claims that DSIP "interacts with hypothalamic sleep centers," or that it modulates serotonin and acetylcholine release, were proposed in the older literature and never established. They are hypotheses, and they should stay labeled that way.

What the sleep studies show — and where they disagree

The human evidence is small, old, and mixed. A handful of European studies in the 1980s reported improved sleep in people with chronic insomnia after intravenous DSIP; other work found no effect, and some reports describe REM suppression rather than the "preserved REM" that promotional pages claim. No modern, large placebo-controlled trial has ever been run.

The concrete record looks like this. A 1981 report in The Lancet described improved sleep in insomniacs given synthetic DSIP. The largest published series, a 1986 sleep-laboratory study, followed 18 adults with chronic psychophysiological insomnia, aged 29 to 83, through one week of intravenous DSIP at 30 nmol/kg body weight (six administrations); sleep measures moved toward normal ranges during treatment and a one-week follow-up. Eighteen people, one week, four decades ago — that is the scale of the strongest human data.

The animal literature does not settle things either. Some studies report longer, more intense slow-wave sleep and shorter sleep latency after DSIP administration; others find no correlation at all. The 2006 review adds a pointed detail: in its authors' own rabbit and rat studies, significant slow-wave-sleep activity came from synthetic structural analogues of DSIP — "but not DSIP itself." Their overall judgment of the sleep-factor hypothesis: "extremely poorly documented and still weak."

Two more gaps matter: larger placebo-controlled trials have never been conducted, and the effects of long-term or repeated administration are unstudied. When a page about DSIP offers "key findings" with no study, year, or participant count attached, treat them as unverified — with this molecule, the unquantified version is usually the inflated one.

The reported endocrine effects

Beyond sleep, older studies report that DSIP lowers basal ACTH — the pituitary hormone that drives cortisol release — and blocks its release, stimulates luteinizing-hormone and growth-hormone secretion, and inhibits somatostatin. On that basis the literature describes it as a "stress-limiting factor." These are reported findings from decades-old work, not established physiology.

If they hold up, they sketch a molecule active in neuroendocrine regulation rather than a simple sleep switch — part of why interest persists in calming and stress-physiology contexts. But the primary studies are old, small, and largely unreplicated, and none supports a promise about what DSIP will do for any given person.

DSIP next to melatonin and prescription sleep aids

Melatonin is a circadian signal — a darkness cue useful for shifting sleep timing, with limited efficacy against chronic insomnia. Benzodiazepines and Z-drugs are effective short-term but carry dependency, tolerance, daytime drowsiness, and disrupted sleep architecture. DSIP is a different and unproven proposition: studied, inconclusively, around the structure of sleep itself.

Melatonin's territory is timing. As the body's darkness signal, it earns its keep resetting rhythms — jet lag, shift work, a drifting schedule — rather than deepening sleep, and clinical guidance finds it of limited use against chronic insomnia. Circadian timing is its own axis of sleep biology, and its own corner of peptide research.

Prescription hypnotics sit at the other pole: benzodiazepines and the non-benzodiazepine Z-drugs reliably shorten the path to sleep in the short term, at the cost of dependency and tolerance risk, next-day drowsiness, and changes to sleep architecture. Those trade-offs are why researchers kept looking at other mechanisms. What DSIP does not have is the evidence base of either comparison: no receptor, no confirmed mechanism, no modern trials.

The July 2026 FDA compounding vote

At the FDA's Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, the committee voted 6–7–1 against recommending DSIP for the 503A bulks list — the list of substances pharmacies may use in compounding. The vote is advisory; rulemaking is pending. DSIP is not an FDA-approved drug and never has been.

In practice: a majority of one voted against list inclusion, and the FDA has not yet issued a final rule. The vote is a data point on how the committee read the evidence, not a verdict on any individual prescription. A licensed provider may still prescribe compounded DSIP where they judge it appropriate — that decision is between you and your doctor.

What a provider weighs with DSIP

DSIP reaches patients, when it does, as a prescription. Through Promise, a licensed provider reviews every request; not everyone qualifies, and the provider can decline when the clinical picture doesn't support prescribing. With DSIP, that picture is unusual: on one side, reported improvements from small, decades-old studies; on the other, an unidentified receptor, an unfound gene, conflicting sleep data, an advisory-committee vote against compounding-list inclusion, and no long-term safety record. A good provider will put all of that on the table, alongside your sleep history and the alternatives — behavioral approaches included. If disrupted sleep is the reason you're reading, that conversation is the useful next step, and it starts with a visit.

This article is for educational purposes only and is not medical advice. DSIP is not FDA-approved, and nothing here is a claim that it will produce any particular result. Talk with a licensed healthcare provider about your own situation.

Common questions

What does DSIP stand for?

Delta sleep-inducing peptide. The name comes from delta waves — the slow, high-amplitude EEG activity of deep sleep — that the Basel researchers were tracking when they isolated the molecule from rabbit blood in the 1970s.

How was DSIP discovered?

The Schoenenberger–Monnier group in Basel, Switzerland, isolated it in the 1970s from the cerebral venous blood of rabbits in an induced sleep state, testing the idea that sleep is carried by a blood-borne factor. The characterization appeared in PNAS in 1977.

Is DSIP FDA-approved?

No. DSIP is not FDA-approved for any use. In July 2026, the FDA's Pharmacy Compounding Advisory Committee also voted 6–7–1 against recommending it for the 503A compounding bulks list; that vote is advisory, and rulemaking is pending. A licensed provider may still prescribe compounded DSIP where appropriate.

Does DSIP improve sleep?

Not established. Small 1980s studies in people with chronic insomnia reported improved sleep measures, but the literature conflicts — some animal studies found more slow-wave sleep, others none — and no modern placebo-controlled trial has tested it.

Is DSIP found naturally in the human body?

Genuinely unknown. No gene encoding DSIP has been found in humans or any other mammal. DSIP-like immunoreactivity has been reported in brain tissue, but researchers have proposed it may belong to a related, still-unidentified peptide rather than DSIP itself.

Why does the missing receptor matter?

A receptor is how a peptide acts on cells. Without one, there is no confirmed mechanism connecting DSIP to sleep — every proposed pathway, from hypothalamic sleep-center interaction to serotonin and acetylcholine modulation, remains a hypothesis rather than a finding.

Is DSIP the same as melatonin?

No. Melatonin is a hormone released in darkness that times the sleep-wake cycle. DSIP is an unrelated nine-amino-acid peptide with an unidentified mechanism, historically studied around sleep structure rather than timing.

What did human studies of DSIP find?

The largest published series followed 18 adults with chronic insomnia given intravenous DSIP — 30 nmol/kg body weight, six doses over one week — in a sleep laboratory, and reported sleep measures moving toward normal ranges. That series, and a few like it from the 1980s, were never replicated with modern methods.

Is DSIP safe?

The short human studies from the 1980s reported it was well tolerated, but the data are limited: small numbers, brief exposure. Long-term and repeated administration have not been studied. Individual safety questions belong in a conversation with a clinician who knows your history.

Do I need a prescription for DSIP?

Yes. Through Promise, DSIP is available only by prescription, and the preparation is compounded by a licensed U.S. pharmacy. There is no over-the-counter version.